Patient disposition by PK category on day 29 steady-state imatinib trough level
| . | Quartile 1, n=87, no, (%) . | Quartiles 2 and 3, n=178, no. (%) . | Quartile 4, n=86, no. (%) . |
|---|---|---|---|
| Still on imatinib up to 5 y | 51 (58.6) | 129 (72.5) | 66 (76.7) |
| Discontinued imatinib | 36 (41.4) | 49 (27.5) | 20 (23.3) |
| Unsatisfactory effect* | 16 (18.4) | 27 (15.2) | 7 (8.1) |
| Adverse event(s)† | 4 (4.6) | 5 (2.8) | 6 (7.0) |
| Death | 1 (1.1) | 4 (2.2) | 1 (1.2) |
| Transplantation | 5 (5.7) | 5 (2.8) | 0 |
| Other reasons‡ | 10 (11.5) | 8 (4.5) | 6 (7.0) |
| . | Quartile 1, n=87, no, (%) . | Quartiles 2 and 3, n=178, no. (%) . | Quartile 4, n=86, no. (%) . |
|---|---|---|---|
| Still on imatinib up to 5 y | 51 (58.6) | 129 (72.5) | 66 (76.7) |
| Discontinued imatinib | 36 (41.4) | 49 (27.5) | 20 (23.3) |
| Unsatisfactory effect* | 16 (18.4) | 27 (15.2) | 7 (8.1) |
| Adverse event(s)† | 4 (4.6) | 5 (2.8) | 6 (7.0) |
| Death | 1 (1.1) | 4 (2.2) | 1 (1.2) |
| Transplantation | 5 (5.7) | 5 (2.8) | 0 |
| Other reasons‡ | 10 (11.5) | 8 (4.5) | 6 (7.0) |
Including 8 patients who crossed over to interferon and cytarabine (IFN+Ara-C) due to lack of response or loss of response (3, 5, and 0 patients, respectively).
Including 2 patients who crossed over to IFN+Ara-C due to intolerance of imatinib.
Other reasons include the following: subject withdrew consent, protocol violation, loss to follow up, abnormal test procedure, and administrative problems.